• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine

tetano

Editor, Senior Moderator
Protein Pept Lett. 2018 Aug 5. doi: 10.2174/0929866525666180806110928. [Epub ahead of print]
[h=1]Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine.[/h] Wang C[SUP]1[/SUP], Zhou J[SUP]1[/SUP], Zhang C[SUP]1[/SUP], Liu Z[SUP]1[/SUP], Liu Y[SUP]1[/SUP], Cai K[SUP]1[/SUP], Shen T[SUP]1[/SUP], Liao C[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Bursal pentapeptide (BPP)-(III-V) are peptides isolated from the bursa of Fabricius (BF). The peptides' adjuvant activities were evaluated in mice immunized with the H9N2 avian influenza vaccine. The results showed that BPP-IV did not promote humoral or cellular immune responses. BPP-III had no effect on antibody production, but increased populations of CD3+ and CD8+ T cells, CTL levels and proliferation activities of splenic T-lymphocytes. BPP-V increased the level of antibodies (HI, IgG and its subtype IgG1) and the cytokine IL-4, as well as the ratio of CD3+ T cells and its subsets CD4+ and CD8+ T cells, BPP-V also increased CTL level and promoted the proliferation activity of T- and B-lymphocyte. Furthermore, in animal challenge experiment, BPP-III and BPP-V reduced viral RNA copies and viral titers, and reduced inflammatory cell infiltration. In summary, BPP-IV did not have an effect on specific immune responses, therefore it could not reduce pathological damage in mice lungs; BPP-III provided resistance to the antigen through the cell-mediated immune response; BPP-V enhanced both humoral and cellular immune responses, and therefore provided protections against the H9N2 avian influenza virus (AIV). Altogether, BPP-III and BPP-V could be adjuvant candidates for the H9N2 avian influenza vaccine.


[h=4]KEYWORDS:[/h]

PMID: 30081784 DOI: 10.2174/0929866525666180806110928
 
Back
Top Bottom